Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro
Received: 2 January 2018
Accepted: 22 January 2018
First Online: 16 February 2018
: Alessandro Morabito was born on September 1, 1967, in Naples, Italy. He received his M.D. degree in 1991 and specialty in Oncology in 1995 at the University Federico II of Naples. Dr Morabito has been the Director of the Medical Oncology Unit, Thoracic-Pulmonary Department of the Istituto Nazionale Tumori, “Fondazione G. Pascale” – IRCCS, Naples since 2010. His research fields of major interest during recent years are lung cancer, target based agents and immunotherapy. Dr. Morabito is an active member of the American Society of Clinical Oncology (ASCO). He has published more than 200 articles in international journals, with an impact factor > 1400 points, a citation index > 12,000, and an H index of 43 (Google Scholar).
: The author has participated in speakers bureaus from Pfizer, AstraZeneca, Roche, Boehringer, Bristol Mayer Squibb, Merck Sharp, and Dohme.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.